A randomized phase III trial in patients with glioblastoma harboring unmethylated methylguanine-DNA methyltransferase (MGMT) promoter showed that the median overall survival of patients treated with standard radiotherapy and nivolumab is shorter than that in patients treated with radiotherapy and temozolomide [324]. This evidence concerns the gene MGMT and glioblastoma.